Last viewed:
AGRX
Prices are updated after-hours
AGRX
|
$0.37
95K
|
Health Technology
(0.0% 1d)
(-38.6% 1m)
(-94.6% 1y)
(0.0% 2d)
(-5.1% 3d)
(0.0% 7d)
(493.29%
volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 2,536,805
http://www.agiletherapeutics.com
Sec
Filling
|
Patents
| 15 employees
(US) Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
contraception
Drugs
Twirla
(levonorgestrel/ethinyl estradiol )
add to watch list
Paper trade
email alert is off
Press-releases
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-28
(Crawled : 12:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| 0.0%
| O: -10.0%
H: 21.62%
C: 2.1%
year
update
therapeutics
financial
results
Agile Therapeutics Announces Delisting from Nasdaq
Published: 2024-03-25
(Crawled : 21:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -38.56%
| O: -60.23%
H: 41.96%
C: 39.46%
nasdaq
therapeutics
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
Published: 2024-03-21
(Crawled : 11:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -36.1%
| O: 0.17%
H: 0.0%
C: -3.28%
report
business
year
update
therapeutics
financial
results
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024Live Conference Call and Webcast at 8:30 a.m. ET
Published: 2024-03-21
(Crawled : 12:00)
- biospace.com/
AGRX
|
$0.37
95K
|
Health Technology
| -36.1%
| O: 0.17%
H: 0.0%
C: -3.28%
conference
report
business
year
update
therapeutics
financial
results
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
Published: 2024-03-20
(Crawled : 12:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -29.87%
| O: 0.55%
H: 9.33%
C: 9.14%
report
business
year
update
therapeutics
financial
results
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Published: 2024-03-13
(Crawled : 12:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -49.25%
| O: 13.85%
H: 0.0%
C: -14.94%
business
therapeutics
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
Published: 2024-02-22
(Crawled : 14:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -62.71%
| O: 32.03%
H: 0.0%
C: -27.68%
million
therapeutics
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
Published: 2024-02-15
(Crawled : 22:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -69.73%
| O: 2.26%
H: 1.6%
C: -4.0%
nasdaq
granted
update
extension
therapeutics
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
Published: 2024-01-23
(Crawled : 14:30)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -75.0%
| O: 0.0%
H: 5.41%
C: -2.03%
contraceptives
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
Published: 2023-12-12
(Crawled : 13:00)
- globenewswire.com
AGRX
|
$0.37
95K
|
Health Technology
| -83.11%
| O: 0.0%
H: 0.0%
C: -6.85%
update
care
contraceptive
therapeutics
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount